Zonghong Shao
Overview
Explore the profile of Zonghong Shao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
192
Citations
1066
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hao S, Zhang Y, Xiao N, Fu R, Shao Z
Hematology
. 2025 Feb;
30(1):2468565.
PMID: 40008495
Objective: Phosphoglycerate kinase 1 (PGK1) was previously screened as a possible autoantigen for IRP, this study further investigates the value of PGK1 autoantibodies in the diagnosis of IRP and their...
2.
Hao S, Zhang Y, Xiao N, Shao Z
Turk J Haematol
. 2025 Jan;
42(1):33-46.
PMID: 39818540
Objective: Immune-related pancytopenia (IRP) is characterized by autoantibody-mediated destruction or suppression of bone marrow cells, leading to pancytopenia. This study aimed to explore the role of trafficking protein particle complex...
3.
Yang L, Zhang M, Liu M, Yu Y, Zhang Y, Yang J, et al.
J Cell Mol Med
. 2025 Jan;
29(1):e70350.
PMID: 39804099
Single-cell sequencing of lineage negative (Lin-) cells from patients with myelodysplastic syndromes (MDS) revealed a reduction in ferritin heavy chain 1 (FTH1) levels, yet the significance of this decrease in...
4.
Kan S, Bai H, Liu H, Cui J, Ke X, Zhang H, et al.
Leuk Res
. 2025 Jan;
149:107633.
PMID: 39799811
Background: Treating relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains challenging. This report extends the three-year follow-up period for the phase Ⅱ YH-S001-04 trial, expanding upon the initial 15.8-month...
5.
Suo S, Fu R, Qin A, Shao Z, Bai J, Zhou H, et al.
Br J Haematol
. 2024 Oct;
205(6):2510-2514.
PMID: 39462216
No abstract available.
6.
Zhang M, Liu M, Yang L, Liu Y, Niu H, Yu Y, et al.
Ann Hematol
. 2024 Aug;
103(10):4009-4020.
PMID: 39177794
Anemia is the most common symptom in patients with myelodysplastic syndromes (MDS). Programmed cell death of erythrocytes is one of the contributing factors to anemia. Ferroptosis is a newly identified...
7.
Yang L, Niu H, Zhang T, Cao Q, Liu M, Liu Y, et al.
Ann Hematol
. 2024 Feb;
103(6):1877-1885.
PMID: 38308019
Pure red cell aplasia (PRCA) is a rare bone marrow disorder characterized by a severe reduction or absence of erythroid precursor cells, without affecting granulocytes and megakaryocytes. Immunosuppressive therapies, particularly...
8.
Yu H, Wang C, Lei Y, Li L, Wang H, Wang G, et al.
Int Immunopharmacol
. 2023 Dec;
127:111232.
PMID: 38091830
To retrospectively analyze the efficacy and safety of venetoclax combined with azacitidine (VEN + AZA) in the treatment of elderly patients with acute myeloid leukemia. The clinical data for 57...
9.
He X, Li N, Liu D, Zang M, Zhao M, Ran N, et al.
Autoimmunity
. 2023 Dec;
56(1):2281225.
PMID: 38053370
Objective: High-throughput sequencing was used to screen expressing differences of miRNA, lncRNA, and mRNA in CD19+ B peripheral blood samples of newly diagnosed immune thrombocytopenia (ITP) patients and healthy controls....
10.
Xia Z, Leng Y, Fang B, Liang Y, Li W, Fu C, et al.
BMC Cancer
. 2023 Oct;
23(1):980.
PMID: 37838670
Background: Aponermin, a circularly permuted tumor necrosis factor-related apoptosis-inducing ligand, is a potential death receptor 4/5-targeted antitumour candidate. Previous phase 1/2 studies have demonstrated the efficacy of aponermin in patients...